Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
LARO
- Cancer Type
- Breast, Central Nervous System, Endocrine, Adrenal, Neuroendocrine, Thymoma, Thyroid, Pancreatic Neuroendocrine, Parathyroid, Gastrointestinal, Anus, Colorectal, Esophagus, Gastric Stomach, Hepatobiliary Liver Bile Duct, Pancreas, Rectal, Small bowel and appendix, Neuroendocrine (GI), Gastrointestinal Stromal Tumours, Mesothelioma (Peritoneal), Genitourinary, Bladder Urothelial, Penile, Prostate, Renal cell Kidney, Testis, Gynecologic, Cervix, Endometrial, Gestational Trophoblastic Disease, Ovary, Uterine Sarcoma, Vulva, Germ Cell, Vagina, Head and Neck, Larynx, Pharynx, Nasopharynx, Paranasal Sinus, Oral, Salivary Gland, Squamous Cell, Kaposi's Sarcoma, Lung, Mesothelioma (Pleural), Non-Small Cell, Small Cell, Neuroendocrine (Lung), Skin, Basal Cell, Merkel Cell, Squamous Cell, Melanoma, Sarcoma, Ewing's, GIST, Osteogenic Bone, Soft Tissue, Ewing's and Soft Tissue, Uterine, Desmoid Tumour, Wilm's Tumour, Giant Cell Tumour, Kaposi's Sarcoma, Unknown Primary
- Intent
-
Palliative
- Regimen Category
-
Evidence-Informed
- Funding Program
-
Exceptional Access Program larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, based on criteria
- Drugs Used
- larotrectinib
Regimen Monograph
Sep 2025
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 21, 2026
